200 related articles for article (PubMed ID: 29257786)
1. Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials.
Zhao MJ; Qin B; Wang JB; Zhang YP; Zhao JT; Mao YG; Zhang XY; Zhang RL
J Clin Psychopharmacol; 2018 Feb; 38(1):55-59. PubMed ID: 29257786
[TBL] [Abstract][Full Text] [Related]
2. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.
Durgam S; Cutler AJ; Lu K; Migliore R; Ruth A; Laszlovszky I; Németh G; Meltzer HY
J Clin Psychiatry; 2015 Dec; 76(12):e1574-82. PubMed ID: 26717533
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies.
Marder S; Fleischhacker WW; Earley W; Lu K; Zhong Y; Németh G; Laszlovszky I; Szalai E; Durgam S
Eur Neuropsychopharmacol; 2019 Jan; 29(1):127-136. PubMed ID: 30470662
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.
Kane JM; Zukin S; Wang Y; Lu K; Ruth A; Nagy K; Laszlovszky I; Durgam S
J Clin Psychopharmacol; 2015 Aug; 35(4):367-73. PubMed ID: 26075487
[TBL] [Abstract][Full Text] [Related]
6. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials.
Citrome L; Durgam S; Lu K; Ferguson P; Laszlovszky I
J Clin Psychiatry; 2016 Jan; 77(1):109-15. PubMed ID: 26845266
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
[TBL] [Abstract][Full Text] [Related]
8. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.
Németh G; Laszlovszky I; Czobor P; Szalai E; Szatmári B; Harsányi J; Barabássy Á; Debelle M; Durgam S; Bitter I; Marder S; Fleischhacker WW
Lancet; 2017 Mar; 389(10074):1103-1113. PubMed ID: 28185672
[TBL] [Abstract][Full Text] [Related]
9. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials.
Corponi F; Serretti A; Montgomery S; Fabbri C
Int Clin Psychopharmacol; 2017 Nov; 32(6):309-318. PubMed ID: 28727644
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data.
Earley W; Guo H; Daniel D; Nasrallah H; Durgam S; Zhong Y; Patel M; Barabássy Á; Szatmári B; Németh G
Schizophr Res; 2019 Feb; 204():282-288. PubMed ID: 30172595
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Cariprazine in Acute Management of Psychiatric Disorders: a Meta-Analysis of Randomized Controlled Trials.
Cooper H; Mishriky R; Reyad AA
Psychiatr Danub; 2020; 32(1):36-45. PubMed ID: 32303028
[TBL] [Abstract][Full Text] [Related]
12. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial.
Durgam S; Litman RE; Papadakis K; Li D; Németh G; Laszlovszky I
Int Clin Psychopharmacol; 2016 Mar; 31(2):61-8. PubMed ID: 26655732
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
Lao KS; He Y; Wong IC; Besag FM; Chan EW
CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
[TBL] [Abstract][Full Text] [Related]
14. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
15. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.
Edinoff A; Ruoff MT; Ghaffar YT; Rezayev A; Jani D; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2020 Sep; 50(4):83-117. PubMed ID: 33012874
[TBL] [Abstract][Full Text] [Related]
16. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial.
Durgam S; Earley W; Li R; Li D; Lu K; Laszlovszky I; Fleischhacker WW; Nasrallah HA
Schizophr Res; 2016 Oct; 176(2-3):264-271. PubMed ID: 27427558
[TBL] [Abstract][Full Text] [Related]
17. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
Citrome L
Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial.
Correll CU; Potkin SG; Zhong Y; Harsányi J; Szatmári B; Earley W
J Clin Psychiatry; 2019 Jan; 80(2):. PubMed ID: 30695290
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Oya K; Kishi T; Iwata N
Hum Psychopharmacol; 2014 Sep; 29(5):483-91. PubMed ID: 25087702
[TBL] [Abstract][Full Text] [Related]
20. Cariprazine: A Review in Schizophrenia.
Garnock-Jones KP
CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
